
iPSC technology provider Axol Bioscience acquires Phenocell
Axol Bioscience has fully acquired Phenocell, though financial terms of the agreement were not disclosed. The acquisition extends Axol’s portfolio of iPSC-derived cell models, adding skin and human retinal iPSC-derived cell lines to its existing neuroscience, pain and touch, and cardiovascular products and services. Read More
